ReviewFrontiers in oncology2025
Early-onset lung cancer in Asia: a narrative review.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Clinicopathological Characteristics, Molecular Findings, and Survival of Lung Cancer in Adults Aged <30 Years in China: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Comprehensive analysis of diverse cytokine patterns in the prognosis and tumor microenvironment of lung adenocarcinoma.Discover oncology · 2026Article
- Clinical characteristics and survival in early-onset lung cancer: a multicenter cohort study.Frontiers in oncology · 2026Article
- Social support, health literacy, perceived control, and health-promoting behaviors in young and middle-aged lung cancer surgical patients: a structural equation model analysis.Frontiers in public health · 2026Article
- Vaping, smoking and risk of early onset lung cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The incidence of early-onset lung cancer (EOLC), often defined as those that occur in adults under the age of 50, is increasing globally. Asia accounted for almost 76% of EOLC cases worldwide. This presents a challenge given previous limited studies and the socioeconomic implications. Methods: References were identified through a PubMed, Scopus and Web of science search for relevant articles published in 2000 to April 2025 using the terms 'lung carcinoma or cancer', 'early-onset' or 'young adults', and 'Asia'. Results: Early-onset lung cancers are more common in female, primarily presenting as adenocarcinoma, and tends to be diagnosed at an advanced stage. There is a high prevalence of potentially targetable genomic alterations: 30-56.3% EGFR mutations and 16.1-50% ALK rearrangements. Comparative analyses show higher prevalence of actionable genetic alterations ROS1, and RET fusions and ERBB2 mutations compared to older patients. Air pollution is a significant risk factor for lung cancer in Asia. MUC16, a transmembrane glycoprotein, is overexpressed in lung cancer, particularly in patients exposed to indoor air pollution. Patients with EOLC exhibit impaired cell-mediated immunity with reduced T cell infiltration. This suggests a potentially limited response to immune checkpoint inhibitor therapies in this patient group. Conclusion: The incidence of EOLC is increasing in Asia. This accounts for 75.9% of global cases. The research conducted in the region are mostly retrospective and, majority are single-institution studies. Due to its unique clinical and molecular features, EOLC requires dedicated research efforts and tailored interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.